Australia's most trusted
source of pharma news
Posted 29 October 2024 AM
The PBAC's "obsession with minimising cost" is hurting families, hurting businesses and hurting Australia, according to a brutally frank review of the reimbursement committee's operations, penned by the Chair of Migraine Australia.
Referring to the drawn out saga of Novartis' migraine drug Aimovig - which is having yet another tilt at reimbursement in November after it's first submission five years ago - the migraine patient group chief, Raphaella Kathryn Crosby, also blamed PBAC for costing tax-payers money.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.